We previously showed pomegranate seed oil and fermented juice polyphenols to retard oxidation and prostaglandin synthesis, to inhibit breast cancer cell proliferation and invasion, and to promote breast cancer cell apoptosis. Here we evaluated the anti-angiogenic potential of these materials in several ways. We checked a possible effect on angiogenic regulation by measuring vascular endothelial growth factor (VEGF), interleukin-4 (IL-4) and migration inhibitory factor (MIF) in the conditioned media of estrogen sensitive (MCF-7) or estrogen resistant (MDA-MB-231) human breast cancer cells, or immortalized normal human breast epithelial cells (MCF-10A), grown in the presence or absence of pomegranate seed oil (SESCO) or fermented juice polyphenols (W). VEGF was strongly downregulated in MCF-10A and MCF-7, and MIF upregulated in MDA-MB-231, overall showing significant potential for downregulation of angiogenesis by pomegranate fractions. An anti-proliferative effect on angiogenic cells was shown in human umbilical vein endothelial cell (HUVEC) and in myometrial and amniotic fluid fibroblasts, and inhibition of HUVEC tubule formation demonstrated in an in vitro model employing glass carrier beads. Finally, we showed a significant decrease in new blood vessel formation using the chicken chorioallantoic membrane (CAM) model in vivo. 'In sum, these varied studies employing different models in different laboratories overall demonstrate for the first time an anti-angiogenic potential of pomegranate fractions, suggesting further in vivo and clinical investigations (for updates: firstname.lastname@example.org).
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Eatock MM, Schatzlein A, Kaye SB. Tumour vasculature as a target for anticancer therapy. Cancer Treat Rev 2000; 26: 191–204.
Pfeffer U, Ferrari N, Morini M et al. Antiangiogenic activity of chemopreventive drugs. Int J Biol Markers 2003; 18: 70–4.
Scappaticci FA. The therapeutic potential of novel antiangiogenic therapies. Expert Opin Invest Drugs 2003; 12: 923–32.
Auerbach R, Lewis R, Shinners B et al. Angiogenesis assays: A critical overview. Clin Chem 2003; 49: 32–40.
Kim ND, Mehta R, Yu W et al. Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat 2002; 71: 203–17.
Fotsis T, Pepper MS, Montesano R et al. Phytoestrogens and inhibition of angiogenesis. Baillieres Clin Endocrinol Metab 1998; 12: 649–66.
Le Marchand L. Cancer preventive effects of flavonoids - a review. Biomed Pharmacother 2002; 56: 296–301.
Sartippour MR, Heber D, Zhang L et al. Inhibition of fibroblast growth factors by green tea. Int J Oncol 2002; 21: 487–91.
Schubert SY, Lansky EP, Neeman I. Antioxidant and eicosanoid enzyme inhibition properties of pomegranate seed oil and fermented juice flavonoids. J Ethnopharmacol 1999; 66: 11–7.
Masso-Welch PA, Zangani D, Ip C et al. Inhibition of angiogenesis by the cancer chemopreventive agent conjugated linoleic acid. Cancer Res 2002; 62: 4383–9.
Kunz-Schughart LA, Knuechel R. Tumor-associated fibroblasts (part I): Active stromal participants in tumor development and progression? Histol Histopathol 2002; 17: 599–621.
Hartlapp I, Abe R, Saeed RW et al. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. FASEB J 2001; 15: 2215–24.
Kapiteijn K, Koolwijk P, Van Der Weiden R et al. Steroids and cytokines in endometrial angiogenesis. Anticancer Res 2001; 21: 4231–42.
Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: Its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001; 2: 667–73.
Nagai S, Toi M. Interleukin-4 and breast cancer. Breast Cancer 2000; 7: 181–6.
Bando H, Matsumoto G, Bando M et al. Expression of macrophage migration inhibitory factor in human breast cancer: Association with nodal spread. Jpn J Cancer Res 2002; 93: 389–96.
Imamura M. Extracellular matrix components and angiogenesis. Nippon Yakurigaku Zasshi 1996; 107: 153–60.
Ueno T, Toi M, Saji H et al. The role of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis and survival of human breast cancer. Clin Cancer Res 2000; 6: 3282–9.
Oikawa T, Sasaki T, Nakamur M et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243–8.
Fife RS, Sledge Jr GW, Sissons S et al. Effects of tetracyclines on angiogenesis in vitro. Cancer Lett 2000; 153: 75–8.
Oikawa T, Hirotani K, Nakamura O et al. A highly potent antiangiogenic activity of retinoids. Cancer Lett 1989; 48: 157–62.
Oikawa T, Hirotani K, Ogasawara H et al. Inhibition of angiogenesis by vitamin D3 analogues. Eur J Pharmacol 1990; 178: 247–50.
Nakamura M, Katsuki Y, Shibutani Y, Oikawa T. Dienogest, a synthetic steroid, suppresses both embryonic and tumor-cellinduced angiogenesis. Eur J Pharmacol 1999; 386: 33–40.
Pavlakovic H, Havers W, Schweigerer L. Multiple angiogenesis stimulators in a single malignancy: Implications for anti-angiogenic tumour therapy. Angiogenesis 2001; 4: 259–62.
Maulik N, Das D. Redox signaling in vascular angiogenesis (1,2). Free Radic Biol Med 2002; 33: 1047.
Leek RD, Talks KL, Pezzella F et al. Relation of hypoxiainducible factor-2 alpha (HIF-2 alpha) expression in tumorinfiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res 2002; 62: 1326–9.
Sasaki H, Ray PS, Zhu L et al. Oxidative stress due to hypoxia/reoxygenation induces angiogenic factor VEGF in adult rat myocardium: Possible role of NFkappaB. Toxicology 2000; 155: 27–35.
Schubert SY, Neeman I, Resnick N. A novel mechanism for the inhibition of NFkB activation in vascular endothelial cells by natural antioxidants. FASEB J 2002; 16: 1931–3.
Sharaf A, Nigm SAR. The oestrogenic activity of pomegranate seed oil. J Endocrinol 1964; 29: 91–2.
Cid MC, Schnaper HW, Kleinman HK. Estrogens and the vascular endothelium. Ann N Y Acad Sci 2002; 966: 143–57.
Gargett CE, Zaitseva M, Bucak K et al. 17Beta-estradiol upregulates vascular endothelial growth factor receptor-2 expression in human myometrial microvascular endothelial cells: Role of estrogen receptor-alpha and-beta. J Clin Endocrinol Metab 2002; 87: 4341–9.
Galea E, Santizo R, Feinstein DL et al. Estrogen inhibits NF kappa B-dependent inflammation in brain endothelium without interfering with I kappa B degradation. Neuroreport 2002; 13: 1469–72.
White RE. Estrogen and vascular function. Vasc Pharmacol 2002; 38: 73–80.
Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothelial growth factor by estrogens and antiestrogens in estrogen-receptor positive breast cancer. Breast Cancer 2002; 9: 39–42.
Nugteren DH, Christ-Hazelhof E. Naturally occurring conjugated octadecatrienoic acids are strong inhibitors of prostaglandin biosynthesis. Prostaglandins 1987; 33: 403–17.
Fukuda R, Kelly B, Semenza GL. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res 2003; 63: 2330–4.
Meyer-Siegler K. COX-2 specific inhibitor, NS-398, increases macrophage migration inhibitory factor expression and induces neuroendocrine differentiation in C4–2b prostate cancer cells. Mol Med 2001; 7: 850–60.
Lansky EP, Jiang WG, Mo H et al. Therapeutic synergy in pomegranate. Poster presented at the 94th Annual Meeting of the American Association for Cancer Research, July 11-14, 2003, Washington, DC.
About this article
Cite this article
Toi, M., Bando, H., Ramachandran, C. et al. Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo . Angiogenesis 6, 121–128 (2003). https://doi.org/10.1023/B:AGEN.0000011802.81320.e4
- breast cancer
- Punica granatum